Clinical and spectroscopic improvement in HIV-associated cognitive impairment
B Stankoff, A Tourbah, S Suarez, E Turell… - Neurology, 2001 - AAN Enterprises
B Stankoff, A Tourbah, S Suarez, E Turell, JL Stievenart, C Payan, A Coutellier, S Herson…
Neurology, 2001•AAN EnterprisesTo assess the impact of highly active antiretroviral therapy (HAART) on AIDS-associated
cognitive impairment, 22 patients with AIDS with (n= 11) and without (n= 11) cognitive deficit
were evaluated clinically and by MRS every 3 months for 9 months. Nineteen patients were
on HAART at study entry, 21 after 2 months. Cognitively impaired patients presented with a
subcorticofrontal deficit and decreased N-acetyl-aspartate in frontal white matter. These
clinical and metabolic abnormalities reversed partially on HAART, whereas they remained …
cognitive impairment, 22 patients with AIDS with (n= 11) and without (n= 11) cognitive deficit
were evaluated clinically and by MRS every 3 months for 9 months. Nineteen patients were
on HAART at study entry, 21 after 2 months. Cognitively impaired patients presented with a
subcorticofrontal deficit and decreased N-acetyl-aspartate in frontal white matter. These
clinical and metabolic abnormalities reversed partially on HAART, whereas they remained …
To assess the impact of highly active antiretroviral therapy (HAART) on AIDS-associated cognitive impairment, 22 patients with AIDS with (n = 11) and without (n = 11) cognitive deficit were evaluated clinically and by MRS every 3 months for 9 months. Nineteen patients were on HAART at study entry, 21 after 2 months. Cognitively impaired patients presented with a subcorticofrontal deficit and decreased N-acetyl-aspartate in frontal white matter. These clinical and metabolic abnormalities reversed partially on HAART, whereas they remained within normal limits in cognitively unimpaired patients.
American Academy of Neurology